Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676 - KALB-TV News Channel 5 & CBS 2

Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Epizyme, Inc.

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias

CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r). This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Including this study, Epizyme now has ongoing assessments of proof-of-concept (POC) in three genetically defined cancer patient groups in the EPZ-5676 clinical program (MLL-r adults, MLL-PTD, and MLL-r pediatrics) with expected data disclosures in the second half of 2014.

"Acute leukemias with MLL-r affect young children and are one of the last remaining forms of childhood leukemia with inadequate treatment options," said Eric Hedrick, M.D., Chief Medical Officer, Epizyme. "Children who are afflicted with this genetically defined cancer have an extremely poor prognosis, especially in comparison to pediatric leukemias without the MLL rearrangement. This pediatric clinical study of EPZ-5676 is an important complement to our ongoing adult studies and reflects our commitment to developing personalized treatments for patients with genetically defined cancers."

"While there has been tremendous progress in improving outcomes for pediatric patients with acute leukemia, patients with MLL-r, a genetically defined leukemia, still present a considerable challenge and a significant area of unmet need," said Lee Greenberger, Ph.D., Chief Scientific Officer, The Leukemia & Lymphoma Society. "We invested in the pre-clinical development of Epizyme's DOT1L inhibitor and applaud Epizyme's efforts as they develop targeted therapies to treat leukemia patients of all ages."

Epizyme is currently enrolling adult MLL-r and MLL-PTD acute leukemia patients in the expansion stage of the adult EPZ-5676 Phase 1 study. In January 2014, Epizyme announced the achievement of a $25 million clinical proof-of-concept milestone in their Celgene collaboration with objective responses observed in two adult MLL-r patients in the fourth cohort of the dose escalation stage of the Phase 1 study, which completed enrollment in December 2013. Epizyme plans to disclose data from the adult Phase 1 dose escalation and expansion stage study for EPZ-5676 in the second half of 2014.

About EPZ-5676  
Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of patients with acute leukemia in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r) or a partial tandem duplication (MLL-PTD). Due to these rearrangements, DOT1L is misregulated, resulting in the increased expression of genes causing leukemia.

Epizyme believes that EPZ-5676 was the first HMT inhibitor to enter human clinical development. Epizyme is currently conducting a two-stage Phase 1 study in adult MLL-r and MLL-PTD patients and in May 2014, initiated a Phase 1b study of EPZ-5676 in pediatric patients with rearrangements of the MLL gene. The adult dose escalation stage has completed enrollment, and the adult MLL-r and MLL-PTD expansion stage is now enrolling patients. Additional information about this ongoing Phase 1 study can be found here: http://clinicaltrials.gov/show/NCT01684150

EPZ-5676 has been granted orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) by the Food and Drug Administration in the U.S. and by the European Commission in Europe.

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the U.S. Epizyme is working with Abbott to develop a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676. Additional information about Epizyme's partnerships is available here: www.epizyme.com/about-us/partnerships/

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc., including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, expectations regarding future clinical trials or expansion of ongoing clinical trials and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, development progress of the Company's companion diagnostics, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2014.  In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KALB. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.